Valuation : Supernus Pharmaceuticals, Inc.

Market Cap 2.54B 2.19B 2.05B 1.88B 3.52B 242B 3.55B 24.35B 9.47B 123B 9.54B 9.34B 406B P/E 2026 *
-219x
P/E 2027 * 35.6x
Enterprise Value 2.54B 2.19B 2.05B 1.88B 3.52B 242B 3.55B 24.35B 9.47B 123B 9.54B 9.34B 406B EV / Sales 2026 *
2.87x
EV / Sales 2027 * 1.85x
Free-Float
95.51%
Yield 2026 *
-
Yield 2027 * -
1 day+0.35%
1 week-2.73%
Current month-1.68%
1 month-1.68%
3 months-1.97%
6 months-19.58%
Current year-11.71%
1 week 42.84
Extreme 42.84
45.86
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 42.45
Extreme 42.45
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/08/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/08/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-2.73%-1.48%+37.81% 2.54B
-0.44%-1.99%+72.75%+35.50% 366B
-0.89%+0.43%+27.87%-16.27% 70.76B
+0.84%-2.26%+44.78%+149.48% 11.96B
-1.33%+2.00%+3.26%-1.02% 8.72B
-0.80%+4.30%-11.46%+0.92% 5B
-1.41%+1.70%-26.26%+21.05% 4.59B
-0.14%-1.37%-28.57%+2.92% 3.16B
-2.27%-3.75%-17.97%-14.26% 2.08B
-1.73%+0.59%-24.09%-14.90% 1.73B
Average -0.83%-0.25%+3.88%+20.12% 47.65B
Weighted average by Cap. -0.57%-1.85%+60.46%+28.90%

Financials

2026 *2027 *
Net sales 886M 763M 716M 654M 1.23B 84.28B 1.24B 8.49B 3.3B 42.74B 3.33B 3.25B 142B 1.37B 1.18B 1.11B 1.01B 1.9B 131B 1.92B 13.14B 5.11B 66.18B 5.15B 5.04B 219B
Net income -11.54M -9.94M -9.33M -8.52M -16M -1.1B -16.12M -111M -43.03M -557M -43.34M -42.4M -1.84B 71.54M 61.6M 57.84M 52.8M 99.18M 6.81B 99.89M 685M 267M 3.45B 269M 263M 11.43B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
31/08/26 US$43.84 +0.25% 307,395
28/08/26 US$43.73 -1.04% 487,925
27/08/26 US$44.19 -1.54% 464,947
26/08/26 US$44.88 -1.06% 499,684
25/08/26 US$45.36 +0.55% 496,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
43.73USD
Average target price
61.75USD
Spread / Average Target
+41.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock